Biotime Inc., of Alameda, Calif., licensed one of its pluripotent cell lines to Nantes, France-based Goliver Therapeutics SAS, a company focused on addressing liver diseases with regenerative technologies. The commercial license will allow Goliver to build on its preclinical work to produce cells for commercial use, Biotime said.